Executive function asymmetry in older adults genetically at-risk for Alzheimer's disease: Verbal versus design fluency

Journal of the International Neuropsychological Society

Volumn 11, Issue 7, 2005, Pages 863-870

  Houston, Wes S ^a   Delis, Dean C ^b,c   Lansing, Amy ^c   Jacobson, Mark W ^b,c   Cobell, Krystal R ^b   Salmon, David P ^c   Bondi, Mark W ^b,c  

^a UNIVERSITY OF IOWA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Aging; APOE; Cognitive discrepancy; Neuropsychology; Normal; Preclinical

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN E EPSILON4; UNCLASSIFIED DRUG;

AGED; AGING; ALZHEIMER DISEASE; ARTICLE; ATTENTION; BRAIN ASYMMETRY; COGNITION; COGNITIVE DEFECT; COMPARATIVE STUDY; CONCEPT FORMATION; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE MARKER; FEMALE; FLUENCY DISORDER; GENETIC RISK; GENOTYPE; HUMAN; HUMAN EXPERIMENT; MALE; MEMORY; NEUROPSYCHOLOGICAL TEST; NONVERBAL COMMUNICATION; NORMAL HUMAN; PERSEVERATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SPATIAL MEMORY; TASK PERFORMANCE; VERBAL COMMUNICATION;

AGED; ALLELES; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; FEMALE; GENOTYPE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; ODDS RATIO; PSYCHOMOTOR PERFORMANCE; RISK; VERBAL BEHAVIOR;

EID: 33644906118     PISSN: 13556177     EISSN: 14697661     Source Type: Journal    
DOI: 10.1017/S1355617705051015     Document Type: Article

References (44)

1. Albert, M.S., Moss, M.B., Tanzi, R., & Jones, K. (2001). Preclinical prediction of AD using neuropsychological tests. Journal of the International Neuropsychological Society, 7, 631-639.
2. Bondi, M.W., Salmon, D.P., Galasko, D., Thomas, R.G., & Thal, L.J. (1999). Neuropsychological function and apolipoprotein E genotype in the preclinical detection of Alzheimer's disease. Psychology and Aging, 14, 295-303.
3. Bondi, M.W., Salmon, D.P., Monsch, A.U., Galasko, D., Butters, N., Klauber, M.R., Thal, L.J., & Saitoh., T. (1995). Episodic memory changes are associated with the APOE-ε allele in nondemented older adults. Neurology, 45, 2203-2206.
4. Bookheimer, S.Y., Strojwas, M.H., Cohen, M.S., Saunders, A.M., Pericak-Vance, M.A., & Mazziotta, J.C. (2000). Patterns of brain activation in people at risk for Alzheimer's disease. New England Journal of Medicine, 343, 450-456.
5. Caselli, R.J., Osborne, D., Reiman, E.M., Hentz, J.G., Barbieri, C.J., Saunders, A.M., Hardy, J., Graff-Radford, G., Hall, G.R., & Alexander, G.E. (2001). Preclinical cognitive decline in late middle-aged asymptomatic apolipoprotein E-e4/4 homozygotes: A replication study. Journal of the Neurological Sciences, 189, 93-98.
6. Chey, J., Kim, J.W., & Cho, H.Y. (2000). Effects of apolipoprotein E phenotypes on the neuropsychological functions of community-dwelling elderly individuals without dementia. Neuroscience Letters, 289, 230-234.
7. Corder, E.H., Saunders, A.M., Strittmatter, W.J., Schmechel, D.E., Gaskell, P.C., Small, G.W., Roses, A.D., Haines, J.L., & Pericak-Vance, M.A. (1993). Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science, 261, 921-923.
8. Craft, S., Teri, L., Edland, S.D., Kukull, W.A., Schellenberg, G., McCormick, W.C., Bowen, J.D., & Larsen, E.B. (1998). Accelerated decline in apolipoprotein E-ε4 homozygotes with Alzheimer's disease. Neurology, 51, 149-151.
9. Delis, D.C., Kaplan, E., & Kramer, J.H. (2001a). The Delis-Kaplan executive function system-examiner's manual. New York: The Psychological Corporation.
10. Delis, D.C., Kaplan, E., & Kramer, J.H. (2001b). The Delis-Kaplan executive function system-technical manual. New York: The Psychological Corporation.
11. Delis, D.C., Massman, P.J., Butters, N., Salmon, D.P., Shear, P.K., Demadura, T., & Filoteo, J.V. (1992). Spatial cognition in Alzheimer's disease: Subtypes of global-local impairment. Journal of Clinical and Experimental Neuropsychology, 14, 463-77.
12. Demadura, T., Delis, D.C., Jacobson, M., & Salmon, D. (2001). Do subgroups of patients with Alzheimer's disease exhibit asymmetric deficits on memory tests? Journal of Clinical and Experimental Neuropsychology, 23, 164-171.
13. Elias, M.F., Beiser, A., Wolf, P.A., Au, R., White, R.F., & D'Agostino, R.B. (2000). The preclinical phase of Alzheimer disease. Archives of Neurology, 57, 808-813.
14. Evans, D.A., Beckett, L.A., Field, T.S., Feng, L., Albert, M.S., Bennett, D.A., Tycko, B., & Mayeux, R. (1997). Apolipoprotein E epsilon4 and incidence of Alzheimer disease in a community population of older persons. Journal of the American Medical Association, 277, 822-824.
15. Finton, M.J., Lucas, J.A., Rippeth, J.D., Bohac, D.L., Smith, G.E., Ivnik, R.J., Petersen, R.C., & Graff-Radford, N.R. (2003). Cognitive asymmetries associated with apolipoprotein E genotype in patients with Alzheimer's disease. Journal of the International Neuropsychological Society, 9, 751-759.
16. Fisher, N.J., Rourke, B.P., & Bieliauskas, L.A. (1999). Neuropsychological subgroups of patients with Alzheimer's disease: An examination of the first 10 years of CERAD data. Journal of Clinical and Experimental Neuropsychology, 21, 488-518.
17. Galasko, D., Kwo-on-Yuen, P.F., Klauber, M.R., & Thal, L.J. (1990). Neurological findings in Alzheimer's disease and normal aging. Archives of Neurology, 47, 625-627.
18. Giacobini, E. (2000). Cholinesterase inhibitors stabilize Alzheimer disease. Neurochemical Research, 25, 1185-1190.
19. Haxby, J.Y., Duara, R., Grady, C.L., Cutler, N.R., & Rapoport, S.I. (1985). Relations between neuropsychological and cerebral metabolic asymmetries in early Alzheimer's disease. Journal of Cerebral Blood Flow and Metabolism, 5, 193-200.
20. Henderson, A.S., Easteal, S., Jorm, A.F., Mackinnon, A.J., Korten, A.E., Christensen, H., Croft, L., & Jacomb, P.A. (1995). Apolipoprotein E allele epsilon 4, dementia, and cognitive decline in a population sample. Lancet, 347, 542.
21. Hogh, P., Knudsen, G.M., Kjaer, K.H., Jorgensen, O.S., Paulson, O.B., & Waldemar, G. (2001). Single photon emission computed tomography and apolipoprotein E in Alzheimer's disease: Impact of the epsilon4 allele on regional cerebral blood flow. Journal of Geriatric Psychiatry and Neurology, 14, 42-51.
22. Jacobs, D.M., Sano, M., Dooneief, G., Marder, K., Bell, K.L., & Stern, Y. (1995). Neuropsychological detection and characterization of preclinical Alzheimer's disease. Neurology, 45, 957-962.
23. Jacobson, M.W., Delis, D.C., Bondi, M.W., & Salmon, D.P. (2002). Do neuropsychological tests detect preclinical Alzheimer's disease: Individual-test versus cognitive-discrepancy score analyses. Neuropsychology, 16, 132-139.
24. Kaplan, E., Goodglass, H. & Weintraub, S. (1983). The Boston Naming Test (2nd ed.). Philadelphia: Lea & Febiger.
25. Lange, K.L., Bondi, M.W., Salmon, D.P., Galasko, D., Delis, D.C., Thomas, R.G., & Thal, L.J. (2002). Decline in verbal memory during preclinical Alzheimer's disease: Examination of the effect of APOE genotype. Journal of the International Neuropsychological Society, 8, 943-955.
26. Linn, R.T., Wolf, P.A., Bachman, D.L., Knoefel, J.E., Cobb, J.L., & Belanger, A.J. (1995). The "preclinical phase" of probable Alzheimer's disease: A 13-year prospective study of the Framingham cohort. Archives of Neurology, 52, 485-490.
27. Martin, A. (1990). Neuropsychology of Alzheimer's disease: The case for subgroups. In M.F. Schwartz (Ed.). Modular deficits in Alzheimer-type dementia (pp. 143-175). Cambridge, MA: The MIT Press.
28. Matarazzo, J.D. & Herman, D.O. (1985). Clinical uses of the WAIS-R: Base rates of differences between VIQ and PIQ in the WAIS-R standardization sample. In B.B. Wolman (Ed.), Handbook of intelligence: Theories, measurements, and applications (pp. 899-932). New York: John Wiley.
29. Mattis, S. (1973). Dementia Rating Scale. Odessa, FL: Psychological Assessment Resources.
30. Mayeux, R., Small, S.A., Tang, M.X., Tycko, B., & Stern, Y. (2001). Memory performance in healthy elderly without Alzheimer's disease: Effects of time and apolipoprotein-E. Neurobiology of Aging, 22, 683-689.
31. Monsch, A.U., Bondi, M.W., Salmon, D.P., Butters, N., Thal, L.J., Hansen, L.A., Wiederholt, W.C., Cahn, D.A., & Klauber, M.R. (1995). Clinical validity of the Mattis dementia rating scale in detecting dementia of the Alzheimer type. A double cross-validation and application to a community-dwelling sample. Archives of Neurology, 52, 899-904.
32. Myers, R.H., Schaefer, E.J., Wilson, P.W.F., D'Agostino, R., Ordovas, J.M., Espino, A., Au, R., White, R.F., Knoefel, J.E., Cobb, J.L., McNulty, K.A., Beiser, A., & Wolf, P.A. (1996). Apoliprotein E element 4 association with dementia in a population-based study: The Framingham study. Neurology, 46, 673-677.
33. Reiman, E.M., Caselli, R.J., Chen, K., Alexander, G.E., Bandy, D., & Frost, J. (2001). Declining brain activity in cognitively normal apolipoprotein E 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proceedings of the National Academy of Sciences, 98, 3334-3339.
34. Reiman, E.M., Caselli, R.J., Yun, L.S., Chen, K., Bandy, D., Minoshima, S., Tibodeau, S.N., & Osborne, D. (1996). Preclinical evidence of Alzheimer's disease in persons homozygous for the ε4 allele for Apolipoprotein E. The New England Journal of Medicine, 334, 752-758.
35. Roses, A.D. (1997). A model for susceptibility polymorphisms for complex diseases: Apolipoprotein E and Alzheimer disease. Neurogenetics, 1, 3-11.
36. Salmon, D.P. & Butters, N.M. (1992). Neuropsychological assessment of dementia in the elderly. In R. Katzman & J.W. Row (Eds.), Principals of geriatric neurology (pp. 144-163). New York: F.A. Davis.
37. Saunders, A.M., Strittmatter, W.J., Schmechel, D., St. George-Hyslop, P.H., Perick-Vance, M.A., Joo, S.H., Rosi, B.L., Gusella, J.F., Crapper-MacLachlan, D.R., Alberts, M.J., Hulette, C., Crain, B., Goldgaber, D., & Roses, A.D. (1993). Association of apolipoprotein E allele ε4 with late-onset familial and sporadic Alzheimer's disease. Neurology, 43, 1467-1472.
38. Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., Kholodenko, D., Lee, M., Liao, Z., Lieberburg, I., Motter, R., Mutter, L., Soriano, F., Shopp, G., Vasquez, N., Vandevert, C., Walker, S., Wogulis, M., Yednock, T., Games, D., & Seubert, P. (1999, July 8). Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature, 400, 173-177.
39. Small, B.J., Basun, H., & Bäckman, L. (1998). Three-year changes in cognitive performance as a function of apolipoprotein E genotype: Evidence from very old adults without dementia. Psychology and Aging, 13, 80-87.
40. Small, G.W., Mazziotta, M.D., Collins, M.T., Baxter, L.R., Phelps, M.E., Mandelkern, M.A., Kaplan, A., La Rue, A., Adamson, C.F., Chang, L., Guze, B.H., Corder, E.H., Saunders, A.M., Haines, J.L., Pericak-Vance, M.A., & Roses, A.D. (1995). Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. Journal of the American Medical Association, 273, 942-947.
41. Smith, G.E., Bohac, D.L., Waring, S.C., Kokmen, E., Tangalos, E.G., Ivnik, R.J., & Petersen, R.C. (1998). Apolipoprotein E genotype influences cognitive "phenotype" in patients with Alzheimer's disease but not in healthy control subjects. Neurology, 50, 355-362.
42. Strittmatter, W.J., Saunders, A.M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G.S., & Roses, A.D. (1993). Apolipoprotein E: High-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proceedings of the National Academy of Sciences (USA), 90, 1977-1981.
43. Warzok, R.W., Kessler, C., Apel, G., Schwarz, A., Egensperger, R., Schreiber, D., Herbst, E.W., Wolf, E., Walther, R., & Walker, L.C. (1998). Apolipoprotein E4 promotes incipient Alzheimer pathology in the elderly. Alzheimer Disease and Associated Disorders, 121, 33-39.
44. Wechsler, D. (1974). Wechsler Intelligence Scale for Children-Revised. San Antonio, TX: The Psychological Corporation.